Hanmi Pharmaceutical said Thursday that Spectrum, Hanmi’s U.S. partner, will conduct two additional cohort studies to verify the possibility of using Poziotinib, a non-small cell lung cancer (NSCLC) treatment, as a first-line treatment.
The study, which is an extension of phase 2 clinical trials in the U.S., which is targeting patients with EGFR or HER2 exon 20 mutations in non-small cell lung cancer, will enroll 140 patients who had never received anti-cancer drugs.
With the two new clinical trials, the phase 2 clinical trial for Poziotinib will now consist of four cohort studies, which Spectrum will conduct in the United States, Canada and Europe. Various global medical institutions such as the University of California Los Angeles (UCLA) Medical Center will be participating in the clinical trials.
“In a situation where it is difficult to provide better treatment options for patients with exon 20 mutations in non-small cell lung cancer, the extended clinical trial for Poziotinib will become an important milestone for patients and medical staff,” said Professor Jonathan Goldman of the department of hematology and oncology at UCLA Medical Center.